{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:49:34Z","timestamp":1768009774936,"version":"3.49.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Studies on late effects in patients with mantle cell lymphoma (MCL) are becoming increasingly important as survival is improving, and novel targeted drugs are being introduced. However, knowledge about late effects is limited. The aim of this population-based study was to describe the magnitude and panorama of late effects among patients treated with or without high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT). The study cohort included all patients with MCL, recorded in the Swedish Lymphoma Register, aged 18 to 69 years, diagnosed between 2000 and 2014 (N\u00a0= 620; treated with HD-ASCT, n\u00a0= 247) and 1:10 matched healthy comparators. Patients and comparators were followed up via the National Patient Register and Cause of Death Register, from 12 months after diagnosis or matching to December 2017. Incidence rate ratios of the numbers of outpatient visits, hospitalizations, and bed days were estimated using negative binomial regression models. In relation to the matched comparators, the rate of specialist and hospital visits was significantly higher among patients with MCL. Patients with MCL had especially high relative risks of infectious, respiratory, and blood disorders. Within this observation period, no difference in the rate of these complications, including secondary neoplasms, was observed between patients treated with and without HD-ASCT. Most of the patients died from their lymphoma and not from another cause or treatment complication. Taken together, our results imply that most of the posttreatment health care needs are related to the lymphoma disease itself, thus, indicating the need for more efficient treatment options.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007241","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T20:12:12Z","timestamp":1660680732000},"page":"866-874","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7063-467X","authenticated-orcid":false,"given":"Sara","family":"Ekberg","sequence":"first","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University and Uppsala Akademiska Hospital, Uppsala, Sweden"},{"name":"2Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[{"name":"2Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden"},{"name":"3Department of Medicine Solna, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Albertsson-Lindblad","sequence":"additional","affiliation":[{"name":"4Division of Oncology, Department of Clinical Sciences Lund, Sk\u00e5ne University Hospital, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6707","authenticated-orcid":false,"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"4Division of Oncology, Department of Clinical Sciences Lund, Sk\u00e5ne University Hospital, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8231-8183","authenticated-orcid":false,"given":"Caroline E.","family":"Weibull","sequence":"additional","affiliation":[{"name":"2Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University and Uppsala Akademiska Hospital, Uppsala, Sweden"},{"name":"2Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"issue":"4","key":"2023081515553513400_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/bloodadvances.2021005715","article-title":"Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes","volume":"6","author":"Castellino","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2023081515553513400_bib2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/imj.14268","article-title":"Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma","volume":"49","author":"Cheah","year":"2019","journal-title":"Intern Med J"},{"issue":"12","key":"2023081515553513400_bib3","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","article-title":"Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"20","author":"Dahi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 3","key":"2023081515553513400_bib4","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"2023081515553513400_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2023081515553513400_bib6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023081515553513400_bib7","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41409-021-01288-9","article-title":"ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma","volume":"56","author":"Munshi","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2023081515553513400_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.16317","article-title":"Comorbidities and sex differences in causes of death among mantle cell lymphoma patients - A nationwide population-based cohort study","volume":"189","author":"Glimelius","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2023081515553513400_bib9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023081515553513400_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"2023081515553513400_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.2014.119115","article-title":"European Mantle Cell Lymphoma N. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?","volume":"101","author":"Dreyling","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"2023081515553513400_bib12","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1016\/S2352-3026(21)00237-4","article-title":"The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma","volume":"8","author":"Chiappella","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"2023081515553513400_bib13","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2023081515553513400_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdh069","article-title":"Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis","volume":"15","author":"Mangel","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"2023081515553513400_bib15","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.clml.2017.11.002","article-title":"Efficacy of standard dose R-CHOP alternating with R-HDAC followed by autologous hematopoietic cell transplantation as initial therapy of mantle cell lymphoma, a single-institution experience","volume":"18","author":"Sawalha","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2023081515553513400_bib16","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/10428190903026518","article-title":"Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma","volume":"50","author":"Tam","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2023081515553513400_bib17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2023081515553513400_bib18","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(21)00195-2","article-title":"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial","volume":"8","author":"Zoellner","year":"2021","journal-title":"Lancet Haematol"},{"issue":"11","key":"2023081515553513400_bib19","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1080\/14740338.2020.1826435","article-title":"The safety of available chemo-free treatments for mantle cell lymphoma","volume":"19","author":"Korycka-Wo\u0142owiec","year":"2020","journal-title":"Expet Opin Drug Saf"},{"issue":"6","key":"2023081515553513400_bib20","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/10428194.2021.1919662","article-title":"Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma","volume":"62","author":"Goyal","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2023081515553513400_bib21","doi-asserted-by":"crossref","first-page":"103038","DOI":"10.1016\/j.critrevonc.2020.103038","article-title":"Mantle cell lymphoma","volume":"153","author":"Cortelazzo","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"2023081515553513400_bib22","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3109\/10428194.2011.587560","article-title":"Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry","volume":"52","author":"Abrahamsson","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2023081515553513400_bib23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"2023081515553513400_bib24","doi-asserted-by":"crossref","DOI":"10.1007\/s10654-016-0117-y","article-title":"Registers of the Swedish total population and their use in medical research","author":"Ludvigsson","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"2023081515553513400_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CLEP.S282475","article-title":"Adaptation of the Charlson Comorbidity Index for register-based research in Sweden","volume":"13","author":"Ludvigsson","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"9","key":"2023081515553513400_bib29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"2023081515553513400_bib26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Publ Health"},{"issue":"4","key":"2023081515553513400_bib27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11764-015-0436-0","article-title":"Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time--a population-based comparative study","volume":"9","author":"Glimelius","year":"2015","journal-title":"J\u00a0Cancer Surviv"},{"issue":"6","key":"2023081515553513400_bib28","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/bloodadvances.2020003645","article-title":"Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival","volume":"5","author":"Glimelius","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2023081515553513400_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"2023081515553513400_bib31","article-title":"Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model","author":"Lambert","year":"2011","journal-title":"Stata Press"},{"issue":"12","key":"2023081515553513400_bib32","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/bloodadvances.2020004167","article-title":"Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma","volume":"5","author":"Dahi","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2023081515553513400_bib33","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1080\/10428194.2017.1326034","article-title":"Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus","volume":"58","author":"Hess","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2023081515553513400_bib34","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma","volume":"18","author":"O'Brien","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2023081515553513400_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11899-019-00520-0","article-title":"Mantle cell lymphoma: which patients should we transplant?","volume":"14","author":"Gerson","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"2023081515553513400_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/17474086.2019.1588106","article-title":"When to use stem cell transplant in mantle cell lymphoma","volume":"12","author":"Greenwell","year":"2019","journal-title":"Expet Rev Hematol"},{"issue":"8","key":"2023081515553513400_bib37","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/bloodadvances.2021004286","article-title":"Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP","volume":"5","author":"Eyre","year":"2021","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/5\/866\/2071237\/blooda_adv-2022-007241-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/5\/866\/2071237\/blooda_adv-2022-007241-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T16:14:20Z","timestamp":1692116060000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/5\/866\/486247\/Late-effects-in-patients-with-mantle-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007241","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]}}}